Leerink Partnrs Issues Negative Estimate for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Agilent Technologies in a report released on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $1.32 per share for the quarter, down from their previous forecast of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.56 EPS and FY2027 earnings at $6.63 EPS.

Agilent Technologies (NYSE:A) last posted its earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the business earned $1.38 earnings per share. Agilent Technologies’s quarterly revenue was up .8% compared to the same quarter last year.

A number of other brokerages have also recently issued reports on A. Evercore ISI lifted their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Stifel Nicolaus restated a “buy” rating and set a $151.00 price objective on shares of Agilent Technologies in a research report on Monday, August 26th. Wells Fargo & Company reduced their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research note on Monday, December 9th. StockNews.com downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, Barclays reduced their price objective on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $143.62.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $134.51 on Friday. The firm has a market capitalization of $38.65 billion, a PE ratio of 30.43, a P/E/G ratio of 4.48 and a beta of 1.07. Agilent Technologies has a 52 week low of $124.16 and a 52 week high of $155.35. The firm’s 50-day simple moving average is $135.85 and its 200 day simple moving average is $136.44. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.248 per share. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. This represents a $0.99 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Tuesday, December 31st. Agilent Technologies’s dividend payout ratio is presently 22.40%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds have recently made changes to their positions in the business. Menard Financial Group LLC grew its position in shares of Agilent Technologies by 1.6% during the second quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after acquiring an additional 77 shares during the last quarter. McAdam LLC boosted its stake in Agilent Technologies by 3.1% during the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 77 shares during the period. Brown Brothers Harriman & Co. grew its position in Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after purchasing an additional 77 shares during the last quarter. Global Retirement Partners LLC grew its position in Agilent Technologies by 3.2% in the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after purchasing an additional 79 shares during the last quarter. Finally, Rovin Capital UT ADV increased its stake in shares of Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares during the period. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.